Lamivudin/Zidovudin Hexal (Zidovudine, Lamivudine)

Lamivudine and Zidovudine, the active ingredients in Lamivudin/Zidovudin Hexal, are nucleoside reverse transcriptase inhibitors presented as oral tablets for systemic use. They are used to treat HIV-1 infection in adults and children, forming part of combination antiretroviral therapy and are prescribed by qualified healthcare professionals.

GNH USA supplies Lamivudin/Zidovudin Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our global distribution network ensures reliable delivery, regulatory compliance, and quality assurance for antiretroviral medicines across diverse markets.

Lamivudin/Zidovudin Hexal is a nucleoside reverse transcriptase inhibitor used effectively in the management of HIV infection worldwide.

- HIV‑1 infection (adults): Provides viral load reduction as part of combination antiretroviral therapy, improving immune function and disease outcomes. - HIV‑1 infection (children): Contributes to viral suppression in pediatric patients when combined with other antiretrovirals, supporting growth and development. - Prevention of mother‑to‑child transmission: Used in pregnant women to lower the risk of HIV transmission to the infant when part of a prescribed regimen.

Lamivudin/Zidovudin Hexal may cause several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset, often transient. - Headache: mild pain or pressure in the head. - Fatigue: generalized tiredness, may affect daily activities. - Anemia: reduced red blood cell count leading to pallor or weakness.

Serious or Rare Side Effects: - Severe lactic acidosis: accumulation of lactate causing metabolic disturbance, requires immediate medical attention. - Hypersensitivity reaction: rash, fever, or organ involvement indicating an allergic response. - Bone marrow suppression: significant drop in blood cell production, increasing infection or bleeding risk.

Before initiating Lamivudin/Zidovudin Hexal, clinicians should consider several precautionary measures to ensure patient safety.

- Monitor blood counts: Perform baseline and periodic CBC to detect anemia or neutropenia. - Assess liver function: Check hepatic enzymes before and during therapy to identify potential toxicity. - Avoid use in patients with known hypersensitivity: Discontinue immediately if allergic reactions occur. - Consider renal function: Adjust dosing in severe renal impairment as per prescriber guidance. - Pregnancy and breastfeeding: Use only if benefits outweigh potential risks to mother and infant. - Store at ambient temperature: Keep below 25 °C, in original packaging, protect from moisture.

Lamivudin/Zidovudin Hexal can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Didanosine: Increased risk of pancreatitis when co‑administered. - Stavudine: Enhanced mitochondrial toxicity leading to peripheral neuropathy. - Alcohol: Exacerbates liver toxicity and may worsen hematologic side effects.

Moderate Interactions (Monitor Closely): - Nevirapine: May raise plasma levels of lamivudine, requiring monitoring. - Efavirenz: Can affect zidovudine metabolism, potentially altering drug concentrations. - Rifampicin: Reduces plasma concentrations of both agents, possibly decreasing antiviral effectiveness.